Objectives: Atazanavir has been associated with kidney stones and renal failure. We measured urine and plasma concentrations of recent protease inhibitors (PIs) and searched for PI crystals in the urine of asymptomatic patients.
Introduction
Atazanavir is a potent HIV protease inhibitor (PI), which is widely used today in both treatment-experienced and treatment-naive patients. Atazanavir was approved in Europe in 2004 as a once-daily dose of 300 mg boosted with 100 mg of ritonavir (ATV300/r). 1, 2 Unboosted atazanavir 400 mg daily has also proved effective as a switch strategy and is approved in the USA. 3 According to current guidelines, atazanavir is one of the first-line drugs because of its high efficacy, tolerability, favourable lipid profile and once-daily dosing. 4, 5 Several years after its approval, the first cases of nephrolithiasis were reported, sometimes leading to obstructive uropathy and acute renal failure. 6 -10 Several cases have established that atazanavir is responsible for this, with high concentrations of atazanavir found in the stones themselves. 8, 10 In other cases, stones were not analysed and therefore the role of atazanavir may only be suspected. 8, 9 Nevertheless, two recent epidemiological studies have found that # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 1850 -1856 doi:10.1093/jac/dkt125 Advance Access publication 18 April 2013 exposure to atazanavir is associated with an increased incidence of renal stones compared with efavirenz and other PI-based regimens. 9, 11 Indinavir, a PI that is less frequently used today because of its toxicity profile, has also been shown to be responsible for precipitation in urine and for clinical sequelae, including chronic renal disease in 4% -43% of patients. 12, 13 Urinary complications due to indinavir were related to high indinavir plasma concentrations and the presence of urinary crystals of indinavir. 13, 14 Other currently used ritonavir-boosted PIs, in particular lopinavir and darunavir, have not been associated with urolithiasis. The reason why atazanavir is associated with urolithiasis is as yet unknown. We therefore searched for crystals in the urine of asymptomatic patients taking different PI regimens and simultaneously measured PI concentrations in the plasma and urine. We compared the clinical and laboratory features of patients receiving atazanavir with those receiving other PIs and, if crystals were found, determined whether there were specific risk factors.
Patients and methods

Patients
We performed a cross-sectional study including HIV-infected adult patients regularly followed in our HIV clinic. Patients could be included if they were receiving a stable antiretroviral regimen including one of the following PIs for at least 30 days on the day of sampling: ATV300/r, unboosted atazanavir 400 mg/day (ATV400), ritonavir-boosted darunavir at a dose of either 800 mg/day (DRV800/r) or 1200 mg/day (DRV1200/r) received as a twice-daily regimen (600/100 mg twice daily) or ritonavir-boosted lopinavir 800 mg/day (LPV800/r) received as a twice-daily regimen (400/ 100 mg twice daily). Steady-state plasma concentrations are usually achieved by day 8 of treatment. We excluded patients with a previous history of urolithiasis or any clinical symptom related to possible urolithiasis (haematuria, acute flank pain or stone passage reported by the patient or a physician) in the past year. This work was approved by the French National Institutional Review Board (Comité de Protection des Personnes, Ile de France n84; IRB 00003835). All patients gave informed consent to participate in the study.
Sampling and drug concentrations
Blood and urine samples were collected simultaneously during a routine follow-up evaluation of HIV infection. Blood samples were used to measure concentrations of PIs as well as plasma HIV viral load, CD4 T cell counts, haematocrit, total bilirubinaemia and creatinine levels. Urine samples were used for PI measurement, urinary pH measurement and crystal analysis. Clinical data including demographic data, history of HIV (date of diagnosis, CDC status and nadir of CD4 cell count), presence of hepatitis coinfection, previous history of urolithiasis and current antiretroviral regimen were collected. Haematocrit was used as an indirect marker of the patient's hydration status at the time of sampling.
Both plasma and urinary PI levels were measured using validated HPLC with tandem mass spectrometry (range 0.05 -10 mg/L, limit of quantification 0.01 mg/L). 15 Patients with undetectable PI levels in their serum were excluded from further analysis as they were assumed to have poor adherence to treatment.
Urinary crystal analysis
Urinary crystal analysis was performed if the sampling conditions were satisfactory (i.e. if the urine sample could be analysed ,3 h after excretion and had been kept at room-air temperature in the initial sampling tube). Crystals were detected by polarized microscopy on fresh urine by the same investigator (M. D.). When crystals were present, they were quantified and analysed by infrared spectrophotometry to determine their composition. Their infrared spectrum was compared with that of PI pills.
Statistics
Patients' characteristics were compared using the x 2 test and Fisher's exact test for categorical variables, and Student's t-test and Wilcoxon rank-sum test for continuous variables, when appropriate. Median drug levels in the plasma and urine and urine-to-plasma ratios were compared using Kruskal-Wallis tests. Post-hoc two-by-two group comparisons used Wilcoxon rank-sum tests after Holm's correction of P values for multiple testing.
To identify risk factors for crystalluria, associations of variables were assessed by univariate analysis (Fisher's exact test for categorical variables and the Mann-Whitney test for continuous variables), comparing patients with and without crystalluria.
A P value ,0.05 was considered to be significant. All analyses were performed using R software version 2.13.2.
Results
Patient characteristics
Both blood and urine samples were available for 266 patients who had agreed to participate in the study. The main characteristics of the patients are shown in Table 1 . The mean age was 46 years (range 21 -74 years); 80% were male. The most frequent mode of infection was men having sex with men (49%), followed by heterosexual transmission (41%). The mean duration of HIV infection was 10.5 years and the current PI regimen had been stable for an average of 22.5 months. The majority of patients had controlled HIV replication (74%) and high CD4 cell counts (mean 494 cells/mm 3 ). Only two patients had a history of urinary stones in their lifetime, one of whom was receiving ATV300/r and one of whom was receiving DRV800/r. Both had presented urinary stones before the beginning of antiretroviral therapy (6 and 4 years prior to this study, respectively). Six patients had previously received indinavir (three in the ATV300/r group, one in the DRV800/r group and two in the LPV800/r group), but none of these patients had experienced urolithiasis.
Drug concentrations
All patients had PI measured in their plasma and urine. The results of the PI measurements are summarized in Figure 1 and Table 2 . The median time from the last drug intake to the taking of the sample (blood or urine) was 10 h (range 0 -28 h). Atazanavir, boosted or not, as well as darunavir (DRV800/r and DRV1200/r) concentrate significantly more in urine than in plasma (all P,0.001), whereas LPV800/r concentrations in plasma and urine were not significantly different. Even though LPV800/r reached higher plasma concentrations than either atazanavir or darunavir (P ¼ 0.008), urinary concentrations of atazanavir and darunavir were significantly higher than those for LPV800/r (P,0.001). Urine-to-plasma concentration ratios were lower for LPV800/r than for each of the other groups (P,0.001).
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Urinary crystals
Crystal analysis was performed in 142 patients (59 receiving ATV300/r, 19 ATV400, 38 DRV800/r, 13 DRV1200/r and 13 LPV800/r). Many samples could not be used for crystal exploration because they (i) had not been sampled properly, (ii) urine samples could not be explored within 3 h of collection or (iii) temperature conditions had not been respected. Patients in whom crystal analysis was performed did not differ from the whole group of patients included in the analysis (Table 1) . Urinary crystals were found in 32 patients (17 of whom were taking atazanavir, 13 darunavir and two lopinavir; P ¼ 0.8).
When the composition of the crystals was analysed by infrared spectrophotometry and compared with the spectrum of PI pills, only 11 patients were carrying PI-containing crystals. The remaining crystals were primarily composed of calcium monohydrate and dihydrate, calcium phosphate and uric acid. Among the patients with PI-containing crystals, atazanavir crystals were found in the urine of 7/78 (8.9%; 95% CI ¼2.6% -15.2%) patients on atazanavir. All patients with atazanavir crystals were receiving ATV300/r. Darunavir crystals were found in the urine of 4/51 (7.8%; 95% CI¼0.4%-15.2%) patients on darunavir (three were receiving DRV800/r and one was receiving DRV1200/r). No crystals were found in any of the patients receiving lopinavir (95% CI¼0%-9.7%). Patients had a median of 5 crystals/mm 3 of urine analysed (range 1-10 crystals/mm 3 ) and all crystals contained at least 50% of pure atazanavir or darunavir. No difference de Lastours et al.
was found in the number of crystals between atazanavir-and darunavir-treated patients (data not shown).
Comparison of patients with or without crystals
A univariate analysis was performed to compare the characteristics of patients in whom urinary crystals were found with those in whom they were not. The results are shown in Table 3 . No statistically significant parameter, in particular urinary pH, PI treatment, creatinine clearance, haematocrit or the presence of another nephrotoxic drug such as tenofovir, was associated with the presence of crystals in the urine. For patients taking atazanavir and darunavir, separate analyses were made to compare patients with and without crystals in terms of plasma and urinary concentrations of atazanavir and darunavir, urine-to-plasma ratios, urinary pH, time since PI treatment and serum bilirubinaemia for atazanavir-treated patients (the second and third parts of Table 3 for patients taking darunavir and atazanavir, respectively). The only factor associated with the presence of atazanavir crystals was the duration of atazanavir therapy, which was longer in patients who had crystalluria (P ¼0.044). There was a trend towards a higher urinary pH in the group with atazanavir crystals (6.3 versus 5.75, P ¼0.37). In relation to darunavir crystalluria, no factor studied here was statistically associated with the presence of crystals in the univariate analysis. Drug concentrations in the urine or plasma were not associated with crystalluria for either of the drugs.
Discussion
We found here that both atazanavir and darunavir concentrate at high levels in the urine. Conversely, lopinavir, which achieved In plasma, concentrations for LPV800/r are significantly higher than those for each of the other groups (P¼0.008). In urine, concentrations of LPV800/r are significantly lower than those for each of the other groups (P,0.001).
a Kruskal-Wallis tests.
Atazanavir and darunavir and the risk of urolithiasis high plasma levels, is poorly excreted in urine, probably explaining why no cases of lopinavir urolithiasis have been described, even though lopinavir has been extensively prescribed worldwide over the last 12 years. Indeed, high urinary excretion, which favours urinary crystallization, is necessary for drugs to produce calculi. 12 Urinary complications in indinavir-treated patients were related to plasma concentrations of indinavir and the presence of urinary crystals of indinavir. 13, 14 Although the incidence of renal colic in patients taking atazanavir is much lower than in those taking indinavir, 9, 11 we found atazanavir crystals in the urine of 8.9% of asymptomatic patients, all taking ritonavirboosted atazanavir. In addition, we found darunavir crystals in the urine of 7.8% of patients treated with darunavir, which to our knowledge has never previously been described. This shows that these drugs can crystallize, which is a first step towards the formation of calculi. Indeed, carriage of drug-containing urinary crystals is always abnormal and is estimated to lead in approximately two-thirds of all cases to lithiasis. Lithiasis formation depends on liquid intake, urinary pH, the quantity of crystals present in the urine and the persistence of crystalluria. 12 The number of crystals found in the urine of our patients was lower (maximum 10/mm 3 ) than that found in indinavir-treated patients (up to 250/mm 3 in our experience). This suggests that indinavir crystallization is more frequent and more important than atazanavir and darunavir crystallization, probably explaining why clinical symptoms are much less frequent with atazanavir than with indinavir. de Lastours et al.
Several risk factors have been suggested to explain atazanavirinduced nephrotoxicity: high serum bilirubinaemia suggesting a slower metabolization of atazanavir; alkaline urine; chronic active hepatitis C, which may impair the liver's clearance of atazanavir and therefore increase renal elimination; longer atazanavir exposure; and a past history of renal stones. 8, 9, 11, 16 One team has suggested that a discontinuation of tenofovir could induce urolithiasis in atazanavir-treated patients because tenofovir decreases the concentration of atazanavir. 17 A recent retrospective work aimed to determine the incidence of urolithiasis in atazanavir-treated patients compared with patients taking other PI regimens (not including darunavir). Thirty-one patients suffered from renal stones and were compared with patients without stones. Several of the above-mentioned risk factors were analysed, but the only independent factor associated with an increased risk of urolithiasis was treatment with boosted atazanavir. 11 Of note, stones occurred an average of 2 years after the start of atazanavir therapy.
We also analysed factors that had been suggested to be involved in stone-formation and found that patients with atazanavir crystals had had a longer atazanavir exposure than those without; there was also a tendency for crystals to be found in patients with an alkaline urinary pH, which is consistent with previous reports. 8, 11, 16 Interestingly, we also found darunavircontaining urinary crystals in a few patients, in accordance with the very high concentrations of darunavir found in the urine, although we failed to identify risk factors for the excretion of darunavir crystals. There has as yet been no clinical report of renal colic or crystalluria in darunavir-treated patients.
Several reasons may explain why no renal stones have ever been described in patients receiving darunavir therapy. First, darunavir was approved in 2006 in the United States for treatment-experienced patients only, approval for treatmentnaive patients following at the end of 2008. Atazanavir was approved in 2004 and has been widely used since then in both treatment-naive and treatment-experienced patients. Fewer patients with HIV are still treated with darunavir than with atazanavir. Second, the duration of exposure to atazanavir seems to be an important feature for risk of urolithiasis, as most patients suffering from renal stones had been taking atazanavir for several years. 8, 10, 16 Finally, the physical properties of darunavir may also explain the differences in occurrence of lithiasis when patients are taking darunavir, but the fact that darunavir crystallization can occur should make us aware of a potential risk of darunavir lithiasis.
No lopinavir crystals were found, which was not surprising considering the low urinary concentrations of lopinavir. Some studies have reported lithiasis in patients treated with lopinavir, but the stones were not analysed so there is no proof that they contained lopinavir. 11, 18 A number of limitations of this study need to be addressed. First, many patients could not undergo urine analysis because of sampling problems. Indeed, in order to perform urinary crystal analysis in good conditions, samples need to be recently excreted, transported at room temperature and analysed within 3 h for clinical relevance to be achieved. It was difficult to achieve this in practice and many samples were therefore excluded. Fortunately, the characteristics of the patients who did and did not undergo urinary crystal analysis did not differ. Second, the number of patients who had crystals was small, which therefore limits the power of the statistical analysis to identify risk factors associated with crystallization. Third, we performed a cross-sectional analysis and therefore only had one urine sample per patient. Recurrent crystalluria is associated with a higher risk of renal colic compared with intermittent crystalluria, so it might have been interesting to follow patients with crystalluria over time so that we could assess the risk of renal colic associated with urinary crystals. 12 Finally, due to the limited number of patients still taking lopinavir in our department, fewer lopinavir-treated patients could be included, and only 13 underwent urinary crystal analysis.
In conclusion, atazanavir crystals, but also darunavir crystals, were found in the urine of a few asymptomatic patients receiving atazanavir-and darunavir-based regimens, in accordance with the very high levels of these drugs found in the urine. There is therefore a potential risk of nephrolithiasis with both drugs, which physicians should be aware of. Further studies are needed to determine specific risk factors that put patients at risk of renal colic.
